Please login to the form below
morphosys
This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
Under the terms of the deal, Incyte is paying MorphoSys $750m upfront, as well as making an equity investment worth $150m in the company. ... MorphoSys is also eligible to receive milestone payments worth up to $1.1bn, in addition to any royalties from
Latest news
-
J&J’s new Darzalex formulation OK’d for use in Europe
More competition could also come from MorphoSys and Takeda, which both have anti-CD38 drugs in late-stage studies for myeloma.
-
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss
Therapy candidate was licensed in a $1bn-plus deal last year. Germany’s MorphoSys has abandoned an atopic dermatitis drug licensed by Novartis in a $1bn-plus deal last year after ... The decision to drop MOR106, a selective IL-17c inhibitor
-
FDA verdict on Sanofi’s Darzalex rival is due in April 2020
Additional competition is however looming from MorphoSys and Takeda, which each have anti-CD38 drugs in pivotal-stage testing for myeloma, while another rival is Bristol-Myers Squibb and AbbVie’s
-
GSK pushes rheumatoid arthritis antibody into phase 3
GSK acquired the rights to otilimab from MorphoSys in a 445m deal agreed in 2013, and the German biotech stands to a receive a 22m milestone payment with the start of
-
MorphoSys eyes 2020 launch for lymphoma CAR-T challenger
New trial data has set up a US filing later this year for MorphoSys’ anti-CD19 antibody tafasitamab (MOR208) – and a possible challenge to Novartis and Gilead’s CAR-T therapies. ... The L-MIND data raise the likelihood of MorphoSys attracting a
More from news
Approximately 5 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
Morphosys. One of Europe’s star performers over the last two to three years has been Germany’s Morphosys. ... Unlike many other European biotechs, Morphosys isn’t seeking a marketing partner for the launch of its lead product, and aims to go it
-
Deal Watch November 2016
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
-
Pharma deals in March 2015
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during August 2014
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Pharma industry appointments
Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Dave Lemus joins Proteros as an executive board member
He has also held roles with MorphoSys and Hoffman La Roche.
-
MorphoSys appoints Dr Markus Enzelberger as CSO
He succeeds Dr Marlies Sproll who resigns. German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation. ... Dr Gerald Moller, supervisory board chairman,
-
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team
She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and investor relations department as senior vice president; a role that saw her
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
Featured jobs
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
-
Vice President
-
Competitive Salary Offered
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Account Director or Senior Account Director
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
-
Consultant
-
competitive salary
Subscribe to our email news alerts
- NantKwest rockets on promising pancreatic cancer data
- NantKwest rockets on promising pancreatic cancer data
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
- J&J wins another label expansion for Darzalex in Europe
- Lucid Group names Neil Flash chief commercial officer
- New hires at bluebird bio, BioNTech and Provention Bio
- IGNIFI expands healthcare team with two new hires
- W2O acquires advertising and medical education agency 21GRAMS
- FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma
- EU group calls for 'targeted actions' to mitigate impact of Brexit
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- White Paper for download - Explaining the price of your product
- In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
- The changing nature of approvals – what does the future hold?
- The 2019 CMR International Pharmaceutical R&D Factbook...
Quick links
Infographics
